SB225002 enhances radiosensitivity in cervical cancer via direct neutrophil inhibition and tumor cell suppression
Cancer Letters · 2026
DOI: 10.1016/j.canlet.2025.218153 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2026. Verfasst von Yanghong Ni und 13 weiteren Autor:innen. Beteiligte Einrichtung: Development and Related Diseases of Women and Children Key Laboratory of Sichuan Province, Key Laboratory of Birth Defects and Related Diseases of Wo…. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Neutrophils, Radiation Tolerance, Phenylurea Compounds. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: West China Hospital of Sichuan University, Ministry of Science and Technology of the People's Republic of China, Sichuan University.
Abstract (Originalsprache)
Radiotherapy resistance is a major contributor to therapeutic failure in cervical cancer, largely due to the immunosuppressive tumor microenvironment (TME). Increasing clinical and experimental evidence underscores the role of neutrophils infiltration in reducing the efficacy of radiation therapy. Additionally, the CXCR2/CXCL signaling axis has been identified as a key regulator of neutrophils recruitment. Our study demonstrates that radiotherapy significantly enhances neutrophils infiltration by activating CXCR2-CXCL signaling and drives their polarization toward a pro-tumor N2-like phenotype through TGF-β signaling in cervical cancer. Further investigation revealed that CXCR2 antagonist SB225002 exerts a synergistic effect with radiotherapy and concurrent chemoradiotherapy in cervical cancer, primarily via inhibiting neutrophils infiltration and alleviating the immunosuppressive TME. Meanwhile, SB225002 exerts direct antitumor activity and enhances the radiosensitivity of cervical cancer cells by facilitating DNA double-strand breaks, promoting G2/M phase cell cycle arrest, and inducing apoptosis. In summary, our findings highlight neutrophils inhibition via CXCR2 antagonist as a promising therapeutic strategy to enhance cervical cancer responsiveness to radiotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Development and Related Diseases of Women and Children Key Laboratory of Sichuan Province, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, Department of Gynecology and…
- Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan, 610…
Förderung
- West China Hospital of Sichuan University
- Ministry of Science and Technology of the People's Republic of China
- Sichuan University
- Sichuan Province Science and Technology Support Program
- National Natural Science Foundation of China
- National Key Research and Development Program of China
Zitieren
APA
Ni, Y., Zhou, X., Tang, Y., Ren, W., Liang, X., Lin, Y., Shi, H., Qing, F., Alu, A., Pi, R., Liu, J., Zhao, X., Luo, M., & Wei, X. (2026). SB225002 enhances radiosensitivity in cervical cancer via direct neutrophil inhibition and tumor cell suppression. Cancer Letters. https://doi.org/10.1016/j.canlet.2025.218153
Vancouver
Ni Y, Zhou X, Tang Y, Ren W, Liang X, Lin Y, et al. SB225002 enhances radiosensitivity in cervical cancer via direct neutrophil inhibition and tumor cell suppression. Cancer Letters. 2026. doi:10.1016/j.canlet.2025.218153
BibTeX
@article{Ni2026,
author = {Ni, Yanghong and Zhou, Xiaoting and Tang, Yan and Ren, Wenyan and Liang, Xiao and Lin, Yi and Shi, Houhui and Qing, Furong and Alu, Aqu and Pi, Ruyu and Liu, Jian and Zhao, Xia and Luo, Min and Wei, Xiawei},
title = {SB225002 enhances radiosensitivity in cervical cancer via direct neutrophil inhibition and tumor cell suppression},
journal = {Cancer Letters},
year = {2026},
doi = {10.1016/j.canlet.2025.218153}
}
EUVIMED